ReviewFrontiers in pharmacology2025
The role of cuproptosis in the occurrence and development of gastric cancer.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The role of copper and cuproptosis in digestive system cancers: novel therapeutic strategies and mechanistic insights.Cancer biology & therapy · 2026Review
- Role of cuproptosis in digestive system tumors (Review).International journal of molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer has emerged as a major global public health threat due to its high incidence and mortality rates. Despite advances in diagnostic and therapeutic approaches, treatment outcomes remain unsatisfactory with frequent disease recurrence and poor prognosis. This underscores the urgent need to develop novel therapeutic strategies against gastric cancer. Cuproptosis, a novel form of cellular death, has garnered increasing attention from researchers regarding its relationship with the onset and progression of gastric cancer. This article aims to explore the molecular mechanisms of cuproptosis, its functions in gastric cancer, and its potential therapeutic applications. We analyze the driving factors and defense mechanisms of cuproptosis, as well as how it influences the growth, metastasis, and drug resistance of gastric cancer cells. Furthermore, we discuss the interplay between cuproptosis and the gastric cancer microenvironment, and consider the possibilities of this mechanism in future clinical treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.